China SXT Pharmaceuticals (STU:2RY1) DeferredTaxAndRevenue: €0.09 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2RY1 China SXT Pharmaceuticals Inc STU:2RY1
48 GF Score
Price €384.00
GF Value €321.31
! 7 Warning Signs
View Full Analysis

What is China SXT Pharmaceuticals DeferredTaxAndRevenue?

China SXT Pharmaceuticals STU:2RY1 48 DeferredTaxAndRevenue is €0.09 Mil as of Mar. 2026. GuruFocus rates STU:2RY1 with a GF Score™ of 48/100 and a GF Value™ of €321.31. The stock has 7 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

China SXT Pharmaceuticals's current deferred tax and revenue for the quarter that ended in Mar. 2026 was €0.09 Mil.

China SXT Pharmaceuticals DeferredTaxAndRevenue Related Terms

China SXT Pharmaceuticals DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for China SXT Pharmaceuticals's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China SXT Pharmaceuticals DeferredTaxAndRevenue Chart

China SXT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.16 0.17 0.06 0.09

China SXT Pharmaceuticals Semi-Annual Data
Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.00 0.06 0.06 0.09
STU:2RY1
48GF Score
China SXT Pharmaceuticals Inc STU:2RY1
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of €0.09 Mil mean?
China SXT Pharmaceuticals (STU:2RY1) has a DeferredTaxAndRevenue of €0.09 Mil as of Mar. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on China SXT Pharmaceuticals.
Is China SXT Pharmaceuticals' DeferredTaxAndRevenue too high?
China SXT Pharmaceuticals' current DeferredTaxAndRevenue is €0.09 Mil. Overall, China SXT Pharmaceuticals has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' DeferredTaxAndRevenue compare to CABR and BFRI?
China SXT Pharmaceuticals' DeferredTaxAndRevenue of €0.09 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Drug Manufacturers company?
A good DeferredTaxAndRevenue depends on the Drug Manufacturers industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on China SXT Pharmaceuticals. China SXT Pharmaceuticals's current DeferredTaxAndRevenue is €0.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
China SXT Pharmaceuticals (STU:2RY1) has a current DeferredTaxAndRevenue of €0.09 Mil. The stock's GF Value™ is €321.31, compared to a current price of €384.00 — trading 19.5% above its estimated fair value. The current DeferredTaxAndRevenue is €0.09 Mil. China SXT Pharmaceuticals' overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For China SXT Pharmaceuticals (STU:2RY1), the current DeferredTaxAndRevenue is €0.09 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China SXT Pharmaceuticals (STU:2RY1) Overvalued in 2026?

Based on GuruFocus' analysis, China SXT Pharmaceuticals stock appears to be overvalued. The current stock price of €384.00 is trading 19.5% above its estimated GF Value™ of €321.31.

Key valuation signals for STU:2RY1:

  • DeferredTaxAndRevenue: €0.09 Mil
  • GF Value™: €321.31 vs. price of €384.00 (19.5% above fair value)
  • GF Score™: 48/100 with 7 warning signs

No single metric tells the full story. See the STU:2RY1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China SXT Pharmaceuticals Business Description

Other Exchanges SXTC:USA
Address No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
48GF Score

Get the complete analysis for STU:2RY1

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€384.00
Price
€321.31
GF Value